NCT06093542View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2024

Conditions

Heathy Participants

Interventions

DRUG

AZD7053

Randomised participants will receive AZD7503 subcutaneously.

DRUG

Placebo

Randomised participants will receive placebo subcutaneously.

Trial Locations (1)

130-0004

Research Site, Sumida-ku

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY